A method for broad-spectrum identification of β-receptor agonist drugs

Abstract

The invention provides a method for broad spectrum identification of beta-receptor stimulant medicines, and relates to the field of medicine testing. According to the method, mass spectrum signals associated with the characteristic chemical structures of the beta-receptor stimulant medicines can be obtained by virtue of an ultra-high-performance liquid chromatography (HPLC)-quadrupole-orbit trap high-resolution mass spectrum device; a characteristic spectrum information base of the beta-receptor stimulant medicines can be built according to the characteristics of mass spectrum signals of the beta-receptor stimulant and the dissociation law of the beta-receptor stimulant. Whether known medicines exist in a sample or not can be identified by comparing high-flux data acquired by the mass spectrum and data in the characteristic spectrum information base; furthermore, whether a novel unknown medicine possibly exists in the sample or not can be predicted by indentifying the modes of the mass spectrum signals; finally, the method for the broad spectrum identification of the beta-receptor stimulant medicines can be formed, so that the beta-receptor stimulant medicines in unknown samples can be rapidly identified. The method provided by the invention has good social benefit and economic benefit.

Description

technical field [0001] The invention relates to the field of drug detection, in particular to a method for broad-spectrum identification of β-receptor agonist drugs. Background technique [0002] Residues of veterinary drugs, additives and harmful compounds are important factors affecting the safety of animal products in our country. The illegal use of β-receptor agonist drugs (commonly known as "clenbuterol") in the breeding process at home and abroad has caused many food safety incidents, resulting in solved the problem of food safety in the world. It not only threatens human health, but also has teratogenic, mutagenic and carcinogenic effects; at the same time, it seriously affects the export trade of livestock and poultry products, causing huge economic losses. The Chinese government has banned the use of "clenbuterol" in animal breeding since 1997. After years of treatment, the results have been remarkable. However, driven by profit, a small number of unscrupulous ope...

AI Technical Summary

Problems solved by technology

For example, the current technology for detecting β-receptor agonist drugs can only monitor a dozen kinds at the same time, but there are dozens or even hundreds of β-receptor agonist drugs that have been reported or studied, and more and more Newly synthesized analogues appear, but existing methods cannot detect them at all, which will cause many β-receptor agonist drugs with similar effects to be mixed in feed and enter the animal body, which seriously restricts the use of "clenbuterol". "Development of regulatory work

[0004] In addition, existing technologies (such as ELISA, HPLC-MS / MS or GC-MS) encounter two limitations when detecting whether there are β-receptor agonist drugs in feed, tissue, blood or urine. On the one hand, rapid detection technologies such as ELISA and test strips can only screen one or two known drugs at a time, and positive samples need to be further confirmed and quantified by mass spectrometry; on the other hand, if HPLC-MS / MS or When GC-MS detects whether an unknown sample contains β-receptor agonist drugs, the practice in the prior art is to exhaustively detect all known standard substances of β-receptor agonist drugs, and then compare the test results with One-to-one comparative screening of whether it contains β-receptor agonists or which β-receptor agonists it contains, but there are many types of standard drugs, expensive, and not easy to obtain, which undoubtedly increases the workload and difficulty of detection

Images